Aardvark Therapeutics, Inc. (NASDAQ:AARD)
| Market Cap | 105.37M-71.9% |
| Revenue (ttm) | 0 |
| Net Income | -69.89M-90.8% |
| EPS | -3.21-89.9% |
| Shares Out | 21.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 125,319 |
| Open | 4.77 |
| Previous Close | 4.96 |
| Day's Range | 4.57 - 5.08 |
| 52-Week Range | 3.35 - 17.23 |
| Beta | 3.81 |
| Analysts | Buy |
| Price Target | 3.00(-37.69%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About AARD
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AARD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AARD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AARD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AARD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AARD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AARD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AARD
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $2.49M |
| VXFVanguard Extended Market ETF | $856.37K |
| IBBiShares Biotechnology ETF | $473.42K |
| IWCiShares Micro-Cap ETF | $198.76K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $120.00K |
| AVSCAvantis U.S. Small Cap Equity ETF | $23.46K |
Estimated from each fund’s disclosed top holdings × AUM
AARD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AARD’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score